Sequence: c[Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Glu]
| Experiment Id | EXP000299 |
|---|---|
| Paper | Engineered Histidine-Enriched Facial Lipopeptides for Enhanced Intracellular Delivery of Functional |
| Peptide | Cyc R9 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 2.5 µM |
| Rna Concentration | 25 nM |
| Mixing Ratio | 100:1 (peptide:siRNA) |
| Formulation Format | Lipopeptide–siRNA nanocomplex |
| Formulation Components | Cyc R9 + siRNA |
| Size Nm | 5.00 |
| Zeta Mv | 5.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-231 (TNBC) |
| Animal Model | |
| Administration Route | |
| Output Type | ERK1/2 mRNA knockdown (RT-qPCR) |
| Output Value | Measured |
| Output Units | |
| Output Notes | Peptides 3, 5, and 6 show strongest knockdown |
| Toxicity Notes | Low toxicity ≤2.5 µM |
| Curation Notes |